National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom

Ameet Bakhai; Marcus D. Flather; Julian R. Collinson; Warren Stevens; Charles Normand; Evo Alemao; Robbin Itzler; Rami Ben-Joseph

doi:10.1016/S0167-5273(03)00023-8

National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom

Ameet Bakhai, Marcus D. Flather, Julian R. Collinson, Warren Stevens, Charles Normand, Evo Alemao, Robbin Itzler, Rami Ben-Joseph

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Acute coronary syndromes without ST elevation are a major health and economic burden. Treatments such as glycoprotein IIb/IIIa antagonists like tirofiban reduce the risk of complications but the cost impact of these agents including cost offsets of avoiding complications are needed particularly in Europe.

Original language	English
Pages (from-to)	163-172
Number of pages	10
Journal	International Journal of Cardiology
Volume	91
Issue number	2-3
DOIs	https://doi.org/10.1016/S0167-5273(03)00023-8
Publication status	Published - Oct 2003

Keywords

Aged
Angina, Unstable
Anticoagulants
Cardiac Catheterization
Coronary Angiography
Coronary Disease
Electrocardiography
Female
Great Britain
Hemorrhage
Heparin
Humans
Male
Middle Aged
Myocardial Infarction
Patient Admission
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Predictive Value of Tests
Prospective Studies
Risk Factors
Sensitivity and Specificity
Syndrome
Treatment Outcome
Tyrosine

Access to Document

10.1016/S0167-5273(03)00023-8

Cite this

@article{07edd35fa6a34b38a5a187c176caa11b,

title = "National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom",

abstract = "Acute coronary syndromes without ST elevation are a major health and economic burden. Treatments such as glycoprotein IIb/IIIa antagonists like tirofiban reduce the risk of complications but the cost impact of these agents including cost offsets of avoiding complications are needed particularly in Europe.",

keywords = "Aged, Angina, Unstable, Anticoagulants, Cardiac Catheterization, Coronary Angiography, Coronary Disease, Electrocardiography, Female, Great Britain, Hemorrhage, Heparin, Humans, Male, Middle Aged, Myocardial Infarction, Patient Admission, Platelet Aggregation Inhibitors, Platelet Glycoprotein GPIIb-IIIa Complex, Predictive Value of Tests, Prospective Studies, Risk Factors, Sensitivity and Specificity, Syndrome, Treatment Outcome, Tyrosine",

author = "Ameet Bakhai and Flather, {Marcus D.} and Collinson, {Julian R.} and Warren Stevens and Charles Normand and Evo Alemao and Robbin Itzler and Rami Ben-Joseph",

year = "2003",

month = oct,

doi = "10.1016/S0167-5273(03)00023-8",

language = "English",

volume = "91",

pages = "163--172",

journal = "International Journal of Cardiology",

issn = "1874-1754",

publisher = "Elsevier",

number = "2-3",

}

TY - JOUR

T1 - National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom

AU - Bakhai, Ameet

AU - Flather, Marcus D.

AU - Collinson, Julian R.

AU - Stevens, Warren

AU - Normand, Charles

AU - Alemao, Evo

AU - Itzler, Robbin

AU - Ben-Joseph, Rami

PY - 2003/10

Y1 - 2003/10

N2 - Acute coronary syndromes without ST elevation are a major health and economic burden. Treatments such as glycoprotein IIb/IIIa antagonists like tirofiban reduce the risk of complications but the cost impact of these agents including cost offsets of avoiding complications are needed particularly in Europe.

AB - Acute coronary syndromes without ST elevation are a major health and economic burden. Treatments such as glycoprotein IIb/IIIa antagonists like tirofiban reduce the risk of complications but the cost impact of these agents including cost offsets of avoiding complications are needed particularly in Europe.

KW - Aged

KW - Angina, Unstable

KW - Anticoagulants

KW - Cardiac Catheterization

KW - Coronary Angiography

KW - Coronary Disease

KW - Electrocardiography

KW - Female

KW - Great Britain

KW - Hemorrhage

KW - Heparin

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Patient Admission

KW - Platelet Aggregation Inhibitors

KW - Platelet Glycoprotein GPIIb-IIIa Complex

KW - Predictive Value of Tests

KW - Prospective Studies

KW - Risk Factors

KW - Sensitivity and Specificity

KW - Syndrome

KW - Treatment Outcome

KW - Tyrosine

U2 - 10.1016/S0167-5273(03)00023-8

DO - 10.1016/S0167-5273(03)00023-8

M3 - Article

C2 - 14559126

VL - 91

SP - 163

EP - 172

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 1874-1754

IS - 2-3

ER -